The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19
| Autor: | Adel El Taguri, Aisha Nasef |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Evidence-based practice Pneumonia Viral lcsh:Medicine Review Article Disease Global Health Antiviral Agents Betacoronavirus 03 medical and health sciences 0302 clinical medicine Drug Discovery Global health Humans Medicine 030212 general & internal medicine Intensive care medicine Pandemics Clinical Trials as Topic clinical trials Evidence-Based Medicine Modalities treatment SARS-CoV-2 business.industry lcsh:R General Medicine Evidence-based medicine sequential analysis Clinical trial Sequential analysis COVID- 19 covid-19 Spite Coronavirus Infections business 030217 neurology & neurosurgery Rare disease |
| Zdroj: | Libyan Journal of Medicine; Vol. 15 No. 1 (2020) Libyan Journal of Medicine Libyan Journal of Medicine, Vol 15, Iss 1 (2020) The Libyan Journal of Medicine article-version (VoR) Version of Record |
| ISSN: | 1993-2820 1819-6357 |
| Popis: | In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the disease is rare or lethal which is particularly so in the case of COVID-19. It is of paramount importance to explore some of the available tools that could help accelerate the adoption of any or some of the many proposed modalities for the treatment of diseases. These tools should be effective, yet efficient, for rapid testing of such treatments. Sequential analysis has not been frequently used in many clinical trials where it should have been used. None of the authors in published literature, as far as we know, used sequential analysis techniques to test potential drugs for COVID-19. In addition to its usefulness when the results of new forms of treatment are quickly needed, other important benefit of sequential analysis includes the ability to reach a similar conclusion about the utility of a new drug without unduly exposing more patients to the side effect of the old drug, in particularly, for the treatment of a rare disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|